LungLife AI, INC Cancellation & Reissue Share Options, PDMR Notice
22 October 2024 - 5:00PM
RNS Regulatory News
RNS Number : 0293J
LungLife AI, INC
22 October 2024
22 October 2024
LungLife AI,
Inc
("LungLife" or the "Company")
Cancellation and Reissue of
Share Options / PDMR Notification
Further to the Company's
announcement on 04 October 2024, LungLife AI (AIM: LLAI), a
developer of clinical diagnostic solutions for lung cancer,
confirms that it has now completed the cancellation and re-issue of
certain options as detailed in that announcement.
As two of the affected option
holders are persons discharging managerial responsibilities,
dealings disclosures for the purposes of the Market Abuse
Regulation are set out below.
For
further information, please contact:
|
LungLife AI, Inc.
|
www.lunglifeai.com
|
|
Paul Pagano,
CEO
|
via
investors@lunglifeai.com
|
|
David Anderson, CFO
|
|
|
|
|
|
Investec Bank plc (Nominated Adviser
& Broker)
|
Tel: +44 (0)20 7597 5970
|
|
Virginia Bull / Lydia
Zychowska/ Sara Wallace
|
|
|
|
|
|
Goodbody (Joint Broker)
|
Tel: +44 (0)
20 3841 6202
|
|
Tom Nicholson / Cameron
Duncan
|
|
About LungLife
LungLife AI is a developer of
clinical diagnostic solutions designed to make a significant impact
in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the Company's
LungLB® test is designed to deliver additional information to
clinicians who are evaluating indeterminate lung nodules. For more
information visit www.lunglifeai.com
Our Purpose is to be a driving force
in the early detection to lung cancer. And our Vision is to
invert the 20:80 ratio such that in years to come at least 80% of
lung cancer is detected early.
The
notification set out below is provided in accordance with the
requirements of MAR.
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
1. Paul
Pagano
2. David
Anderson
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
1. Chief Executive
Officer
2. Chief Financial
Officer
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
LungLife AI, Inc.
|
|
b)
|
LEI
|
549300VBVDIF0Y3OVI38
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Options over Ordinary
Shares
|
|
|
|
|
Identification code
|
ISIN: USU5500L1045
|
|
|
|
|
b)
|
Nature of the transaction
|
Cancellation and re-issue of Options
over Ordinary Shares pursuant to the 2021 Omnibus Long Term
Incentive Plan
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price
|
Volume(s)
|
|
|
|
|
1. Nil
|
769,707
|
|
|
|
|
2. Nil
|
386,703
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
N/A
|
|
|
|
|
- Aggregated volume
|
|
|
|
|
|
- Price
|
|
|
|
|
|
e)
|
Date of the transaction
|
18 October 2024
|
|
f)
|
Place of the transaction
|
Outside of a trading
venue
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
MSCVFLFLZBLFFBQ
Lunglife Ai (LSE:LLAI)
Historical Stock Chart
From Oct 2024 to Nov 2024
Lunglife Ai (LSE:LLAI)
Historical Stock Chart
From Nov 2023 to Nov 2024
